Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
Date:8/2/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 2, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced financial results for its second quarter and six months ended June 30, 2012 and provided an overview of the clinical development activities of its two product candidates, custirsen and OGX-427.

Custirsen Clinical Development Highlights

  • The Company announced detailed plans for the ENSPIRIT trial, an international, randomized Phase 3 study in approximately 1,100 patients with advanced or metastatic non-small cell lung cancer (NSCLC). The trial will evaluate the potential survival benefit of combining custirsen with docetaxel as a second-line treatment in patients who have progressed after initial chemotherapy treatment has failed. Enrollment is planned to begin later this year and the trial will be managed by our development partner for custirsen, Teva Pharmaceuticals Industries LTD (TEVA).
  • Custirsen's primary registration Phase 3 study, SYNERGY, evaluating a survival benefit for custirsen plus first-line chemotherapy in patients with castrate-resistant prostate cancer (CRPC), remains on schedule and patient accrual is expected to be completed in the second half of 2012.
  • The Phase 3 AFFINITY study, evaluating a survival benefit for custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in patients with CPRC, is expected to begin patient enrollment in the near future.
  • OGX-427 Clinical Development Highlights

  • Preliminary data from an investigator-sponsored Phase 2 clinical trial of OGX-427 in chemotherapy-naive patients with metastatic CRPC were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2012. Preliminary study results showed a higher number of patients without disease progression at 12 weeks and greater declines in prostate
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
    10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
    11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)...  Decision Resources Group is launching an extension of ... now include ChinaTrack; the new capabilities track the ... dashboard providing detailed brand-level share tracking and analytics. ChinaTrack ... Other key capabilities of the new line ... to end-user surveys of healthcare facilities, ChinaTrack data is ...
    (Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 /PRNewswire/ ... committee members—who make decisions about which therapies are ... influence formulary placement, according to a new Manhattan ... Makers 2014 . The study finds that P&T ... and pharmacy benefits managers (PBMs) have set a ...
    (Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
    Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Touro University California Garners Grant From Long Foundation 2
    ... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
    ... 22 Amedisys, a leading home health care and hospice company ... on the future of home care in this week,s issue of ... of the Amedisys Strategic Advisory Board. Titled, "Why ... on the future of home care as an increasingly crucial component ...
    Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Media Statement From Amedisys on Dr. Steven H. Landers' NEJM Commentary on the Future of Home Care 2
    (Date:7/31/2014)... Atlanta-based Jvion, a leader in clinical ... lessons in predictive population health analytics as part of ... analytics in healthcare. Ritesh Sharma, Jvion COO, commented, “it ... to understand the impact of and potential within predictive ... and a good portion of it is conflicting or ...
    (Date:7/31/2014)... During the July 2014 board meeting of the ... executive director of the Mesothelioma Applied Research Foundation, Mary ... promising clinical trials to choose from than ever before. ... have been reporting increased survival and response rates. Some ... is within the field of immunotherapy. One trial, ...
    (Date:7/31/2014)... ANN ARBORA new bill introduced in Congress with bipartisan ... from University of Michigan research, which could improve the ... they spend on the medicines and tests they need ... Reps. Diane Black and Earl Blumenauer, grew out of ... with the U-M,s Institute for Healthcare Policy and Innovation. ...
    (Date:7/31/2014)... Jacuzzi Luxury Bath, the company ... a new and improved website to meet the needs ... Luxury Bath website has been redesigned to offer a ... represented by the company’s products. The design is current, ... bathroom applications. “The site reflects our Jacuzzi® brand standards, ...
    (Date:7/31/2014)... drug, researchers at The Wistar Institute discovered that ... with fewer age-related illnesses. The mice, which lack ... degeneration, obesity, and spontaneous tumor formation when compared ... scientists view the metabolic networks within cells. ... regulator of metabolism and has been shown to ...
    Breaking Medicine News(10 mins):Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 2Health News:Jvion Releases Top Three Lessons in Predictive Population Health Analytics 3Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 2Health News:‘More Promising Mesothelioma Clinical Trials than Ever Before,’ Says Expert 3Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 2Health News:'Rewired' mice show signs of longer lives with fewer age-related illnesses 3
    ... planning to phase out junk food and make exercise mandatory, ... Department to counter childhood obesity//. , ,These recommendations follow ... were being sent to dieticians. , ,The NSW report, ... the biggest study of its kind in the country. The ...
    ... been awarded with discount shopping cards in return for ... clinic as part of the HIV/AIDS awareness program//. ... Nation's AIDS-prevention agency India has largest number of people, ... virus. ,Sushena Reza-Paul of the Karnataka Health ...
    ... Pradesh today in protest against dismissal of AIIMS director ... junior doctors observed a `symbolic' strike and a large ... some time condemning the sacking of Venugopal., ,Terming ... the strike was "symbolic and we have no intention ...
    ... Manchester is reportedly treating patients with mouth and throat cancer ... ,Sources at the Manchester cancer hospital explained that ... doctors at Christie Hospital in Didsbury, Manchester, are planning to ... clinical trail basis. They hope to try and reduce the ...
    ... expressed their concerns over the practice of "Breast Ironing" ... is used to stunt breast growth in girls by mothers// ... own good. ,It is aimed at warding off ... objects pressed against the developing breasts in teenaged girls. "Breast ...
    ... is brandishing a piece of his own skull, an ... visitors//. ,The Jawaharlal Nehru Memorial Hospital in Kalyani, ... no less visitors than any museum these days with ... getting electrocuted from a high-voltage wire, holding his own ...
    Cached Medicine News:Health News:Man Holds Own Skull in Bengal Medical Miracle 2
    Abdominal Binder w / Velcro...
    Ideal for abdominal, flank, hip and thigh procedures....
    Male high waisted compression girdle with CDIs Wonderfabric™...
    This high waist tummy tuck girdle provides the same CDI Wonderfabric™ compression as the 8000 series....
    Medicine Products: